Thelansis

 Peripheral T-cell lymphoma (PTCL) is a rare group of typically fast-growing Non-Hodgkin's Lymphomas (NHL) that originates from mature T-cells and natural killer (NK) cells, which are mature-stage white blood cells. This subtype of NHL specifically affects T-cells and occurs when these cells develop and proliferate abnormally. Patients diagnosed with PTCL often face a grim prognosis characterized by multiple relapses and resistance to initial treatment. Relapsed or Refractory Peripheral T-cell lymphoma refers to a condition where the disease reappears or grows again after a period of remission (relapsed) or when the lymphoma does not respond to treatment (refractory), meaning that the cancer cells continue to grow, or when the response to treatment does not last very long. Median overall survival for relapsed patients had a longer survival period at 29.1 months compared to refractory patients with only 12.3 months. One-year survival rates are influenced by the response to the initi